Gaurav Aggarwal insider trades: Sierra Oncology (SRRA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Gaurav reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 31, 2022 | SRRA | ↑ Buy | 800,000 | $27.00 | $21.6M | By Vivo Opportunity Fund, L.P. | Jan 31, 2022 (0d) |
| Jan 15, 2016 | OCRX | ↑ Buy | 10,000 | $2.15 | $22K | Direct | Jan 19, 2016 (4d) |
| May 6, 2015 | OCRX | ↑ Buy | 7,500 | $3.62 | $27K | Direct | May 6, 2015 (0d) |
| Jul 31, 2012 | HPTX | ↑ Buy | 5,000 | $10.00 | $50K | Direct | Aug 2, 2012 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Gaurav Aggarwal's insider trades
Gaurav Aggarwal is a director at Sierra Oncology (SRRA). Since Jul 31, 2012, Gaurav has reported 4 open-market purchases worth $21.7M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (14 filings), conversions (5 filings), shares returned to the company (4 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SRRA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.